In the global landscape of health technology, Landing Med is charting its own remarkable course through innovation and influence. Recently, the "Chasing the Chinese Dream: 2025 Global Chinese Media Tour of Jingchu" was launched in Wuhan. As a pioneering force in China's AI-powered medical sector, Landing Med welcomed 20 overseas Chinese-language media outlets and international guests for an in-depth visit. This cross-border engagement was not only a powerful testament to Landing Med's technological prowess, but also a vivid example of Chinese innovation serving global health.
Within just one week, the Landing Med Science and Technology Park became a hub of international dialogue. A delegation from Iraq's Ministry of Health signed a cooperation agreement on site, while representatives from Chinese-language media in 20 countries—including Malaysia and Côte d’Ivoire—along with national and provincial media, visited Landing Med to explore its innovation firsthand. Dr. Sun Xiaorong, founder of Landing Med, personally presented the company's AI cervical cancer screening technology to 24 domestic and international media organizations—offering the world a direct view into Landing Med's leadership in the health tech space.
During the event, Mr. Xu Xiangzhong, Secretary of the Party Committee and Chairman of the Wuhan Overseas Chinese Federation, praised Landing Med's achievements in an interview. "Landing Med's AI screening technology is at the forefront globally. By leveraging a large number of intelligent diagnostic robots and advanced cloud-based systems, including their innovative all-in-one portable digital pathology slide scanner, they've amassed vast datasets. This technology is not only cost-effective, but also delivers high-quality and efficient services that benefit women's health in Hubei, across China, and worldwide. I believe Landing Med has immense potential, and its innovation deserves broad application. It stands as a powerful example of Chinese strength in healthcare innovation and offers valuable insight and solutions to the global health community'.
In recent years, Landing Med's international network has expanded significantly. With friends from over 60 countries visiting the company, eight new nations joined its partnership list just within the past year. Its roster of high-level international supporters includes:
Moin ul Haque, Ambassador of Pakistan to China.
Dr. Roma Chilengi, Health Advisor to the President of Zambia.
Dr. Norman Zerbe, President of the European Society of Digital Pathology.
Dr. Junya Fukuoka, President of the Asian Society of Digital Pathology.
Oyungerel, Social Policy Advisor to the President of Mongolia as well as international scholars from Oxford University, Yale University, and other global academic institutions.
Under the backdrop of globalization, Landing Med continues to seek and deepen international cooperation. Its technology has already been implemented in multiple countries, and new agreements have been reached with Morocco, Peru, Brazil, and others. Over the past year alone, Landing Med has been invited to share its innovations abroad multiple times, proudly representing the strength and appeal of Chinese health technology.
From the 2024 USCAP (United States & Canadian Academy of Pathology) Annual Meeting, to the upcoming 2025 Global AI Health Summit in Singapore, Landing Med has made its presence felt at leading international conferences and forums. At each of these events, the company has not only presented its latest technological breakthroughs but also engaged in critical exchanges with global experts, helping drive forward the development of global health technology.
Landing Med's rising global reputation stems from its unparalleled achievements in health tech. As the builder of the world's largest AI-powered digital pathology cloud platform for cervical cancer screening, powered by technologies like their high throughput cytology slide scanner, and the provider of the world's largest free cervical cancer screening programs, and a contributor to AI cervical cancer screening standards in Asia, Landing Med has achieved breakthroughs recognized across the industry. Its independently developed AI technology enables automated, intelligent, and highly accurate cervical cancer screening, supported by a comprehensive ecosystem that includes essential cytology consumables—dramatically improving both efficiency and precision. In addition, the company actively promotes the widespread adoption of free screening technology in underserved regions.
Today, Landing Med brings the spirit to life: "AI knows no borders—its impact can be extraordinary". Standing at a new global starting point, Landing Med is ready to join hands with partners around the world, using the power of technology to bridge health disparities. Together, we aim to bring the light of intelligent healthcare to every corner of the earth—and write a new chapter in the story of the "Health Silk Road".
fr 
es 
CN
